SG11201400988SA - Compounds and methods for enhancing innate immune responses - Google Patents

Compounds and methods for enhancing innate immune responses

Info

Publication number
SG11201400988SA
SG11201400988SA SG11201400988SA SG11201400988SA SG11201400988SA SG 11201400988S A SG11201400988S A SG 11201400988SA SG 11201400988S A SG11201400988S A SG 11201400988SA SG 11201400988S A SG11201400988S A SG 11201400988SA SG 11201400988S A SG11201400988S A SG 11201400988SA
Authority
SG
Singapore
Prior art keywords
compounds
methods
immune responses
innate immune
enhancing innate
Prior art date
Application number
SG11201400988SA
Other languages
English (en)
Inventor
Anna Lindsey Banka
Janos Botyanszki
Eric Gregory Burroughs
John George Catalano
Wendy Huang Chern
Hamilton D Dickson
Margaret J Gartland
Robert Hamatake
Hans Hofland
Jesse Daniel Keicher
Christopher Brooks Moore
John Bradford Shotwell
Matthew David Tallant
Jean-Philippe Therrien
Shihyun You
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of SG11201400988SA publication Critical patent/SG11201400988SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG11201400988SA 2011-10-21 2012-10-19 Compounds and methods for enhancing innate immune responses SG11201400988SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161549784P 2011-10-21 2011-10-21
US201261692431P 2012-08-23 2012-08-23
PCT/US2012/060971 WO2013059559A2 (en) 2011-10-21 2012-10-19 Compounds and methods for enhancing innate immune responses

Publications (1)

Publication Number Publication Date
SG11201400988SA true SG11201400988SA (en) 2014-07-30

Family

ID=48141628

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201400988SA SG11201400988SA (en) 2011-10-21 2012-10-19 Compounds and methods for enhancing innate immune responses
SG10201505664WA SG10201505664WA (en) 2011-10-21 2012-10-19 Compounds and methods for enhancing innate immune responses

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201505664WA SG10201505664WA (en) 2011-10-21 2012-10-19 Compounds and methods for enhancing innate immune responses

Country Status (22)

Country Link
US (1) US20140249143A1 (es)
EP (1) EP2768506A4 (es)
JP (1) JP2014532626A (es)
KR (1) KR20140094559A (es)
CN (1) CN103957910A (es)
AR (1) AR088793A1 (es)
AU (1) AU2012325971B2 (es)
BR (1) BR112014008727A2 (es)
CA (1) CA2851801A1 (es)
CL (1) CL2014001016A1 (es)
CO (1) CO6910198A2 (es)
CR (1) CR20140175A (es)
DO (1) DOP2014000081A (es)
EA (1) EA201490610A1 (es)
IL (1) IL231894A0 (es)
MX (1) MX2014004814A (es)
PE (1) PE20141359A1 (es)
SG (2) SG11201400988SA (es)
TW (2) TW201542567A (es)
UY (1) UY34406A (es)
WO (1) WO2013059559A2 (es)
ZA (1) ZA201402392B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103333168B (zh) * 2013-07-23 2015-08-05 清华大学 一种酰胺类化合物及其制备方法与应用
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
JP2017531631A (ja) * 2014-09-29 2017-10-26 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 伝染性軟属腫ウイルスに対する抗ウイルス薬
CN104529893B (zh) * 2014-12-30 2016-08-24 中国科学技术大学 一类可以作为高尔基体细胞器探针的喹啉染料
CN105175277B (zh) * 2015-05-18 2018-04-03 中山大学肿瘤防治中心 一种3‑磷酸甘油醛脱氢酶的抑制剂及其制备方法和应用
WO2018043747A1 (ja) * 2016-09-05 2018-03-08 国立大学法人京都大学 抗b型肝炎ウイルス剤
WO2018183540A1 (en) 2017-03-28 2018-10-04 Pimera, Inc. Novel crystal forms of a pol1 inhibitor
AU2019363569A1 (en) 2018-10-23 2021-04-29 Basf Se Tricyclic pesticidal compounds
CN114732822B (zh) * 2019-03-13 2023-06-30 中国人民解放军军事科学院军事医学研究院 氨基葡萄糖及其衍生物作为抗病毒药物的应用
CN115427408A (zh) 2020-04-14 2022-12-02 巴斯夫欧洲公司 杀害虫的三环化合物
WO2022049521A1 (en) * 2020-09-03 2022-03-10 Glaxosmithkline Intellectual Property Development Limited Imidazonaphthyridines and imidazopyridopyrimidines as ifnar2 agonists for treating sars-cov-2 infections
WO2022175425A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Intellectual Property Development Limited Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection
US11939328B2 (en) 2021-10-14 2024-03-26 Incyte Corporation Quinoline compounds as inhibitors of KRAS
WO2023244672A1 (en) 2022-06-14 2023-12-21 Assembly Biosciences, Inc. 2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL59104A (en) * 1979-02-09 1984-02-29 Roussel Uclaf Heterotricyclic derivatives,process for their preparation and pharmaceutical compositions incorporating them
US4492697A (en) * 1983-08-16 1985-01-08 Ayerst, Mckenna & Harrison, Inc. 4H-Imidazo[2,3-c]pyrido[2,3-e][1,4]oxazine derivatives
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
CA2479644A1 (en) * 2002-04-03 2003-10-09 F. Hoffmann-La Roche Ag Imidazo fused compounds
US8592368B2 (en) * 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
DE102005019181A1 (de) * 2005-04-25 2006-10-26 Novartis Ag Peptid-Deformylase (PDF) Inhibitoren 1
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
WO2010113416A1 (ja) * 2009-03-31 2010-10-07 ダイキン工業株式会社 高分子アクチュエータ素子用電極膜及びそれを有する高分子アクチュエータ素子
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB201002409D0 (en) * 2010-02-12 2010-03-31 Univ Nottingham Methods

Also Published As

Publication number Publication date
WO2013059559A3 (en) 2013-11-14
EA201490610A1 (ru) 2014-09-30
CL2014001016A1 (es) 2015-01-16
KR20140094559A (ko) 2014-07-30
UY34406A (es) 2013-05-31
PE20141359A1 (es) 2014-10-13
SG10201505664WA (en) 2015-09-29
TW201333003A (zh) 2013-08-16
CA2851801A1 (en) 2013-04-25
US20140249143A1 (en) 2014-09-04
WO2013059559A2 (en) 2013-04-25
CN103957910A (zh) 2014-07-30
JP2014532626A (ja) 2014-12-08
EP2768506A4 (en) 2015-08-19
AU2012325971A1 (en) 2014-04-17
TW201542567A (zh) 2015-11-16
CO6910198A2 (es) 2014-03-31
EP2768506A2 (en) 2014-08-27
ZA201402392B (en) 2017-09-27
MX2014004814A (es) 2014-05-27
DOP2014000081A (es) 2014-07-15
CR20140175A (es) 2014-06-03
BR112014008727A2 (pt) 2017-04-25
IL231894A0 (en) 2014-05-28
AU2012325971B2 (en) 2016-03-31
AR088793A1 (es) 2014-07-10

Similar Documents

Publication Publication Date Title
IL231894A0 (en) Compounds and methods for enhancing innate immune responses
HK1243344A1 (zh) 抗體製劑和方法
ZA201307919B (en) Composition and method for enhancing an immune response
EP2753362A4 (en) MATERIALS AND METHODS FOR MODULATING THE IMMUNE RESPONSE
EP2736330A4 (en) COMPOUNDS AND METHODS
EP2751748A4 (en) METHOD AND ARRANGEMENTS FOR IDENTIFYING OBJECTS
EP2784830A4 (en) LED DEVICE AND METHOD FOR PREPARING THE SAME
EP2788507A4 (en) METHOD FOR MEASURING IMMUNE ACTIVATION
EP2747560A4 (en) CONNECTIONS AND METHODS
EP2663857A4 (en) METHOD OF DETECTION OF PROTEINS
EP2736332A4 (en) CONNECTIONS AND METHODS
EP2736329A4 (en) COMPOUNDS AND METHODS
EP2672606A4 (en) DEVICE FOR CHARGING CHECK AND METHOD FOR CHARGING CHECK
EP2700357A4 (en) CONCENTRATION MEASUREMENT DEVICE AND CONCENTRATION METHOD
GB201110783D0 (en) Methods and uses
GB201122089D0 (en) Telecomunication apparatus and methods
GB201116774D0 (en) Uses and methods
SG11201408326TA (en) Preparation method for perfluoro-2-methyl-3-pentanone and intermediate
HK1199402A1 (en) Beta-lactam compounds for enhancing t cell -mediated immune responses t-
EP2717985A4 (en) DEVICE AND METHOD FOR DISTILLATION
HK1197004A1 (en) Multicarotenoid beadlets and related method
EP2723375A4 (en) MATERIALS AND METHODS FOR MODULATING IMMUNE REACTIONS
EP2837624A4 (en) 4-SUBSTITUTE-2-HYDROXYLMORPHOLIN-3-ON AND METHOD OF MANUFACTURING THEREOF
GB201105569D0 (en) Apparatus and methods
EP2829603A4 (en) PROTEIN REGISTRATION PROCEDURES